Advances in progesterone delivery systems: Still work in progress?
[Display omitted] Progesterone is a natural steroidal sex hormone in the human body, mainly secreted through the adrenal cortex, ovary, and placenta. In humans, progesterone is essential for endometrium transformation in the uterus at the time of ovulation and maintenance of pregnancy. When the body...
Gespeichert in:
Veröffentlicht in: | International journal of pharmaceutics 2023-08, Vol.643, p.123250-123250, Article 123250 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 123250 |
---|---|
container_issue | |
container_start_page | 123250 |
container_title | International journal of pharmaceutics |
container_volume | 643 |
creator | Patil, Nikhil Maheshwari, Ronak Wairkar, Sarika |
description | [Display omitted]
Progesterone is a natural steroidal sex hormone in the human body, mainly secreted through the adrenal cortex, ovary, and placenta. In humans, progesterone is essential for endometrium transformation in the uterus at the time of ovulation and maintenance of pregnancy. When the body cannot produce enough progesterone for specific ailments, it is administered via different routes such as oral, vaginal, transdermal, topical, parental, and intranasal routes. Although progesterone is commercially available in multiple conventional formulations, low solubility, less permeability and extensive hepatic first-pass metabolism are the major constraints to its delivery. These challenges can be overcome substantially by formulating progesterone into novel delivery systems like lipid carriers, polymeric carriers, hydrogels, several nanocarriers, depot and controlled release systems. Various research papers and patents have been published in the last two decades on progesterone delivery systems; clinical studies were conducted to establish safety and efficacy. This review is focused on the pharmacodynamic and pharmacokinetic parameters of progesterone, its delivery constraints, and various advanced delivery systems of progesterone. |
doi_str_mv | 10.1016/j.ijpharm.2023.123250 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2841024804</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517323006701</els_id><sourcerecordid>2841024804</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-3be5ca77ca52ba48bbc62fb836a01ceaee37021dd439a687536f6cf5459683f33</originalsourceid><addsrcrecordid>eNqFkE1PwzAMhiMEYmPwE0A9culI4uZjXKYx8SVN4gCcozR1IaNdR9IN7d_TaRtXTpasx37th5BLRoeMMnkzH_r58tOGesgphyHjwAU9In2mFaSQKXlM-hSUTgVT0CNnMc4ppZIzOCU9UJlmdCT75G5SrO3CYUz8IlmG5gNji6FZYFJg5dcYNkncdK063iavra-q5KcJXwc4YIzjc3JS2irixb4OyPvD_dv0KZ29PD5PJ7PUgRRtCjkKZ5VyVvDcZjrPneRlrkFayhxaRFCUs6LIYGSlVgJkKV0pMjGSGkqAAbne7e2Sv1fdnab20WFV2QU2q2i4zhjlmaZZh4od6kITY8DSLIOvbdgYRs1Wn5mbvT6z1Wd2-rq5q33EKq-x-Js6-OqA8Q7A7tG1x2Ci89j5K3xA15qi8f9E_AJutoOi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2841024804</pqid></control><display><type>article</type><title>Advances in progesterone delivery systems: Still work in progress?</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><creator>Patil, Nikhil ; Maheshwari, Ronak ; Wairkar, Sarika</creator><creatorcontrib>Patil, Nikhil ; Maheshwari, Ronak ; Wairkar, Sarika</creatorcontrib><description>[Display omitted]
Progesterone is a natural steroidal sex hormone in the human body, mainly secreted through the adrenal cortex, ovary, and placenta. In humans, progesterone is essential for endometrium transformation in the uterus at the time of ovulation and maintenance of pregnancy. When the body cannot produce enough progesterone for specific ailments, it is administered via different routes such as oral, vaginal, transdermal, topical, parental, and intranasal routes. Although progesterone is commercially available in multiple conventional formulations, low solubility, less permeability and extensive hepatic first-pass metabolism are the major constraints to its delivery. These challenges can be overcome substantially by formulating progesterone into novel delivery systems like lipid carriers, polymeric carriers, hydrogels, several nanocarriers, depot and controlled release systems. Various research papers and patents have been published in the last two decades on progesterone delivery systems; clinical studies were conducted to establish safety and efficacy. This review is focused on the pharmacodynamic and pharmacokinetic parameters of progesterone, its delivery constraints, and various advanced delivery systems of progesterone.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2023.123250</identifier><identifier>PMID: 37481096</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Contraceptive ; Delivery constraints ; Novel delivery systems ; Pharmacokinetic parameters ; Progesterone</subject><ispartof>International journal of pharmaceutics, 2023-08, Vol.643, p.123250-123250, Article 123250</ispartof><rights>2023 Elsevier B.V.</rights><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-3be5ca77ca52ba48bbc62fb836a01ceaee37021dd439a687536f6cf5459683f33</citedby><cites>FETCH-LOGICAL-c365t-3be5ca77ca52ba48bbc62fb836a01ceaee37021dd439a687536f6cf5459683f33</cites><orcidid>0000-0002-0124-1741</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijpharm.2023.123250$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37481096$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Patil, Nikhil</creatorcontrib><creatorcontrib>Maheshwari, Ronak</creatorcontrib><creatorcontrib>Wairkar, Sarika</creatorcontrib><title>Advances in progesterone delivery systems: Still work in progress?</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted]
Progesterone is a natural steroidal sex hormone in the human body, mainly secreted through the adrenal cortex, ovary, and placenta. In humans, progesterone is essential for endometrium transformation in the uterus at the time of ovulation and maintenance of pregnancy. When the body cannot produce enough progesterone for specific ailments, it is administered via different routes such as oral, vaginal, transdermal, topical, parental, and intranasal routes. Although progesterone is commercially available in multiple conventional formulations, low solubility, less permeability and extensive hepatic first-pass metabolism are the major constraints to its delivery. These challenges can be overcome substantially by formulating progesterone into novel delivery systems like lipid carriers, polymeric carriers, hydrogels, several nanocarriers, depot and controlled release systems. Various research papers and patents have been published in the last two decades on progesterone delivery systems; clinical studies were conducted to establish safety and efficacy. This review is focused on the pharmacodynamic and pharmacokinetic parameters of progesterone, its delivery constraints, and various advanced delivery systems of progesterone.</description><subject>Contraceptive</subject><subject>Delivery constraints</subject><subject>Novel delivery systems</subject><subject>Pharmacokinetic parameters</subject><subject>Progesterone</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkE1PwzAMhiMEYmPwE0A9culI4uZjXKYx8SVN4gCcozR1IaNdR9IN7d_TaRtXTpasx37th5BLRoeMMnkzH_r58tOGesgphyHjwAU9In2mFaSQKXlM-hSUTgVT0CNnMc4ppZIzOCU9UJlmdCT75G5SrO3CYUz8IlmG5gNji6FZYFJg5dcYNkncdK063iavra-q5KcJXwc4YIzjc3JS2irixb4OyPvD_dv0KZ29PD5PJ7PUgRRtCjkKZ5VyVvDcZjrPneRlrkFayhxaRFCUs6LIYGSlVgJkKV0pMjGSGkqAAbne7e2Sv1fdnab20WFV2QU2q2i4zhjlmaZZh4od6kITY8DSLIOvbdgYRs1Wn5mbvT6z1Wd2-rq5q33EKq-x-Js6-OqA8Q7A7tG1x2Ci89j5K3xA15qi8f9E_AJutoOi</recordid><startdate>20230825</startdate><enddate>20230825</enddate><creator>Patil, Nikhil</creator><creator>Maheshwari, Ronak</creator><creator>Wairkar, Sarika</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0124-1741</orcidid></search><sort><creationdate>20230825</creationdate><title>Advances in progesterone delivery systems: Still work in progress?</title><author>Patil, Nikhil ; Maheshwari, Ronak ; Wairkar, Sarika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-3be5ca77ca52ba48bbc62fb836a01ceaee37021dd439a687536f6cf5459683f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Contraceptive</topic><topic>Delivery constraints</topic><topic>Novel delivery systems</topic><topic>Pharmacokinetic parameters</topic><topic>Progesterone</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patil, Nikhil</creatorcontrib><creatorcontrib>Maheshwari, Ronak</creatorcontrib><creatorcontrib>Wairkar, Sarika</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Patil, Nikhil</au><au>Maheshwari, Ronak</au><au>Wairkar, Sarika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances in progesterone delivery systems: Still work in progress?</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2023-08-25</date><risdate>2023</risdate><volume>643</volume><spage>123250</spage><epage>123250</epage><pages>123250-123250</pages><artnum>123250</artnum><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted]
Progesterone is a natural steroidal sex hormone in the human body, mainly secreted through the adrenal cortex, ovary, and placenta. In humans, progesterone is essential for endometrium transformation in the uterus at the time of ovulation and maintenance of pregnancy. When the body cannot produce enough progesterone for specific ailments, it is administered via different routes such as oral, vaginal, transdermal, topical, parental, and intranasal routes. Although progesterone is commercially available in multiple conventional formulations, low solubility, less permeability and extensive hepatic first-pass metabolism are the major constraints to its delivery. These challenges can be overcome substantially by formulating progesterone into novel delivery systems like lipid carriers, polymeric carriers, hydrogels, several nanocarriers, depot and controlled release systems. Various research papers and patents have been published in the last two decades on progesterone delivery systems; clinical studies were conducted to establish safety and efficacy. This review is focused on the pharmacodynamic and pharmacokinetic parameters of progesterone, its delivery constraints, and various advanced delivery systems of progesterone.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>37481096</pmid><doi>10.1016/j.ijpharm.2023.123250</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0124-1741</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-5173 |
ispartof | International journal of pharmaceutics, 2023-08, Vol.643, p.123250-123250, Article 123250 |
issn | 0378-5173 1873-3476 |
language | eng |
recordid | cdi_proquest_miscellaneous_2841024804 |
source | Elsevier ScienceDirect Journals Complete - AutoHoldings |
subjects | Contraceptive Delivery constraints Novel delivery systems Pharmacokinetic parameters Progesterone |
title | Advances in progesterone delivery systems: Still work in progress? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A31%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances%20in%20progesterone%20delivery%20systems:%20Still%20work%20in%20progress?&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Patil,%20Nikhil&rft.date=2023-08-25&rft.volume=643&rft.spage=123250&rft.epage=123250&rft.pages=123250-123250&rft.artnum=123250&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2023.123250&rft_dat=%3Cproquest_cross%3E2841024804%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2841024804&rft_id=info:pmid/37481096&rft_els_id=S0378517323006701&rfr_iscdi=true |